ECSP22049014A - Variantes de progranulina - Google Patents

Variantes de progranulina

Info

Publication number
ECSP22049014A
ECSP22049014A ECSENADI202249014A ECDI202249014A ECSP22049014A EC SP22049014 A ECSP22049014 A EC SP22049014A EC SENADI202249014 A ECSENADI202249014 A EC SENADI202249014A EC DI202249014 A ECDI202249014 A EC DI202249014A EC SP22049014 A ECSP22049014 A EC SP22049014A
Authority
EC
Ecuador
Prior art keywords
progranulin
variants
proteins
ftd
polypeptide
Prior art date
Application number
ECSENADI202249014A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Ray L Y Low
Gerald Maxwell Cherf
Ankita Srivastava
Katrina W Lexa
Rachel Prorok
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of ECSP22049014A publication Critical patent/ECSP22049014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente variantes de progranulina y prote?nas de fusi?n que comprenden una variante de progranulina y un polip?ptido Fc. Tambi?n se proporcionan en la presente m?todos para el uso de dichas prote?nas para el tratamiento de trastornos asociados con la progranulina (por ejemplo, una enfermedad neurodegenerativa, tal como demencia frontotemporal (FTD)).
ECSENADI202249014A 2019-12-23 2022-06-21 Variantes de progranulina ECSP22049014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962953099P 2019-12-23 2019-12-23
US202063091819P 2020-10-14 2020-10-14

Publications (1)

Publication Number Publication Date
ECSP22049014A true ECSP22049014A (es) 2022-07-29

Family

ID=74184961

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249014A ECSP22049014A (es) 2019-12-23 2022-06-21 Variantes de progranulina

Country Status (17)

Country Link
US (4) US20210188925A1 (es)
EP (1) EP4081536A1 (es)
JP (1) JP7904130B2 (es)
KR (1) KR20220130678A (es)
CN (1) CN114981297A (es)
AU (1) AU2020411480B2 (es)
BR (1) BR112022012230A2 (es)
CA (1) CA3165846A1 (es)
CL (1) CL2022001712A1 (es)
CO (1) CO2022008648A2 (es)
EC (1) ECSP22049014A (es)
IL (1) IL293994A (es)
MX (1) MX2022007486A (es)
PE (1) PE20230036A1 (es)
PH (1) PH12022551598A1 (es)
TW (1) TW202138384A (es)
WO (1) WO2021133907A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用
EP4731669A2 (en) 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier
WO2025051953A1 (en) * 2023-09-07 2025-03-13 Novo Nordisk A/S Sortilin-1 binders, constructs and uses thereof
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
WO2026075889A1 (en) 2024-10-04 2026-04-09 Eli Lilly And Company Compositions comprising a progranulin domain for the prevention and treatment of neurodegenerative diseases
EP4755905A1 (en) 2024-12-05 2026-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Truncated progranulin protein and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110938A1 (en) 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2002236499A1 (en) 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050123962A1 (en) 2003-10-28 2005-06-09 Agy Therapeutics, Inc. Regulated nucleic acids in pathogenesis of alzheimer's disease
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
JP5123936B2 (ja) 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療
EP2687223B2 (en) 2006-05-30 2024-11-20 Mayo Foundation For Medical Education And Research Detecting and treating dementia
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
US7928068B2 (en) 2007-01-31 2011-04-19 New York University Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders
DE102007033359B4 (de) 2007-07-16 2010-12-02 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
JP5822822B2 (ja) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
CA2818253A1 (en) 2010-11-16 2012-05-24 Denis G. Kay Method for increasing neprilysin expression and activity
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
AR085138A1 (es) 2011-02-04 2013-09-11 Genentech Inc VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP5855239B2 (ja) 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
EA032681B1 (ru) 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
CA3166758A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
EP3035969B1 (en) 2013-08-19 2022-08-03 S.M. Discovery Holdings Inc. Peptidic nanodelivery composition targeting two receptors
US10357542B2 (en) 2014-02-04 2019-07-23 New York University Progranulin (PGRN) and its derivatives for diagnosis and treatment of lysosomal storage diseases
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
JP7021955B2 (ja) 2015-06-24 2022-03-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
GB201512215D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11390656B2 (en) 2015-08-04 2022-07-19 New York University Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2018013775A2 (en) 2016-07-14 2018-01-18 Emory University Granulin compositions and uses related thereto
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
WO2019032955A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
BR112020013921A2 (pt) 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
WO2019203555A1 (ko) 2018-04-17 2019-10-24 한국생명공학연구원 Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
WO2019246071A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
CA3109763A1 (en) 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
EP3840781A1 (en) 2018-08-22 2021-06-30 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof
US20210396772A1 (en) 2018-10-16 2021-12-23 Denali Therapeutics Inc. Methods for treating and monitoring progranulin-associated disorders
EP3894864A2 (en) 2018-12-10 2021-10-20 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
EP4229419A2 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia

Also Published As

Publication number Publication date
CL2022001712A1 (es) 2023-03-24
US20230265137A1 (en) 2023-08-24
EP4081536A1 (en) 2022-11-02
MX2022007486A (es) 2022-06-29
PE20230036A1 (es) 2023-01-10
US11643446B2 (en) 2023-05-09
PH12022551598A1 (en) 2023-11-20
CN114981297A (zh) 2022-08-30
IL293994A (en) 2022-08-01
US20220213155A1 (en) 2022-07-07
WO2021133907A1 (en) 2021-07-01
KR20220130678A (ko) 2022-09-27
JP2023507846A (ja) 2023-02-27
TW202138384A (zh) 2021-10-16
US20210188925A1 (en) 2021-06-24
CA3165846A1 (en) 2021-07-01
CO2022008648A2 (es) 2022-06-30
US20220220172A1 (en) 2022-07-14
AU2020411480A1 (en) 2022-06-30
JP7904130B2 (ja) 2026-08-12
BR112022012230A2 (pt) 2022-08-30
AU2020411480B2 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
CO2022008648A2 (es) Variantes de progranulina
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
SA520411662B1 (ar) بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم
MX378790B (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
UY40283A (es) Método para alterar una propiedad de una planta
CR20190480A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
JOP20220068A1 (ar) بروتينات اندماج nkg2d واستخداماتها
CO2020013557A2 (es) Variantes de lfa3 y composiciones y usos de las mismas
AR115565A1 (es) Proteínas de fusión que comprenden progranulina
EA202190062A1 (ru) Слитые белки, содержащие програнулин
AR120892A1 (es) Variantes de progranulina
AR119984A1 (es) Proteínas de fusión nkg2d y sus usos
AR114938A1 (es) Variantes de expresión de cdkl5 y proteínas de fusión cdkl5
UA115420U (xx) Спосіб відновлення деталей